Summarized by Masters of Longevity from Longevity Technology.
Galimedix announced plans for a biomarker‑driven Phase 2a study of oral GAL‑101.

Key Takeaways
- Galimedix plans a biomarker‑driven Phase 2a trial called SAPHARY.
- They will test GAL‑101 in Down syndrome‑associated Alzheimer’s proof‑of‑concept.
- The planned study is observationally biomarker‑driven and not causal proof.



